TET2 and acute myeloid leukemia: MEG3 is significantly downregulated in AML patients’ tissue samples and cell lines when compared to normal controls, particularly in the Wilms’ tumor 1 (WT1) or ten–eleven translocation 2 (TET2) mutant AML patients [92,345,346].